NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) A
Post# of 111
(Total Views: 211)
Posted On: 10/21/2022 5:18:32 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, the trials will be performed in autoimmune diseases, first studying psoriasis. Dr. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of multinational pharmaceutical company Schering AG’s therapeutics business unit, is leading Adimune’s(TM) ADI(TM) immune modulation technology development toward clinical trials. “The impact of Adimune’s(TM) approach to treating autoimmune disease may have a game changing impact in a worldwide market estimated at more than 1.2 million type 1 diabetes patients under the age of 20 and another 125 million psoriasis patients,” said Dr. Kapp. “The ADI(TM) technology is very different from immunosuppressant drugs in that it restores immune tolerance. Our proof-of-concept trials are designed to demonstrate just that.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, the trials will be performed in autoimmune diseases, first studying psoriasis. Dr. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of multinational pharmaceutical company Schering AG’s therapeutics business unit, is leading Adimune’s(TM) ADI(TM) immune modulation technology development toward clinical trials. “The impact of Adimune’s(TM) approach to treating autoimmune disease may have a game changing impact in a worldwide market estimated at more than 1.2 million type 1 diabetes patients under the age of 20 and another 125 million psoriasis patients,” said Dr. Kapp. “The ADI(TM) technology is very different from immunosuppressant drugs in that it restores immune tolerance. Our proof-of-concept trials are designed to demonstrate just that.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼